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Dear Editor,
Crack cocaine use has increased in Brazil in recent years and 
is already considered an epidemic. It is a cheaper form of 
cocaine use but is much more damaging to the body. There 
are few treatments available for the public, particularly 
low-cost treatments. Some clinical trials have demonstrated 
VXFFHVVZLWKWKHDGPLQLVWUDWLRQRIGLVXOÀUDPDVDQDGGRQ
therapy in patients with cocaine dependence.1-3 However, no 
VWXG\KDVHYDOXDWHGWKHHIÀFDF\DQGVDIHW\RIWKLVPHGLFDWLRQ
in crack cocaine addiction. 
This double-blind pilot study followed 30 patients with 
crack cocaine dependence who spontaneously sought out 
the Psychosocial Attention Center for Alcohol and Drugs of 
Palmas, Brazil. The study assessed the effectiveness and 
VDIHW\RIGLVXOÀUDPDVDQDGGRQ WKHUDS\ WRPRWLYDWLRQDO
interviewing and group therapy in patients with crack cocaine 
dependence. The inclusion criteria were as follows: male; 
subjects with a diagnosis of crack cocaine dependence ac-
cording to the 10thHGLWLRQRIWKH,QWHUQDWLRQDO&ODVVLÀFDWLRQ
of Diseases (ICD-10); and age between 18 and 40 years. The 
exclusion criteria were as follows: negative history of crack 
cocaine dependence, physical illness or another psychiatric 
disorder; use of another drug; and unable or unwilling to 
consent. The presence of another psychiatric disorder was 
assessed by a psychiatrist that used the ICD-10 diagnostic 
criteria.Seventy-four subjects were assessed, and 30 patients 
had a diagnosis of dependence.
The subjects were randomly divided by permuted blocks 
into two groups; 15 subjects (28.6 ± 4.4 years of age) re-
FHLYHGPJRIGLVXOÀUDPGDLO\IRUGD\VDQGFRQWUROV
(matched by gender, age and diagnosis) received placebo. 
The subjects were compared regarding the following factors: 
(i) treatment adherence (number of subjects who received 
treatment for the full 60 days); (ii) frequency of drug use 
(mean of number of days per week that crack cocaine was 
used); (iii) drug dose (daily mean dose of crack cocaine used 
in grams); and (iv) drug-free rate (number of subjects that 
VWRSSHGFUDFNFRFDLQHXVHDIWHUGD\VFRQÀUPHGE\XUL-
nalysis); (v) side-effects. All subjects were assessed weekly 
by a psychiatrist who also used motivational interviewing. 
The subjects participated in eight sessions of motivational 
interviewing and group therapy during the study. Patients who 
abandoned treatment continued the motivational interview-
ing and group psychotherapy with a psychiatrist. 
$IWHUGD\VVXEMHFWVLQWKHGLVXOÀUDPJURXS
and 10 (67%) in the control group completed the treatment 
S 'LVXOÀUDPUHGXFHGWKHGUXJIUHTXHQF\EDVHOLQH
4.9 ± 1.5 days/week, endpoint 0.6 ± 0.2 days/week, effect 
size -4.7 ± 2.6) when compared to the control group (baseline 
4.5 ± 1.4 days/week, endpoint 1.4 ± 0.9 days/week, effect 
VL]H    S    'LVXOÀUDPDOVR SURPRWHG WKH
reduction of the mean drug dose used per day (baseline 
3.9 ± 1.5 g, endpoint 0.6 ± 0.2 g, effect size -3.7 ± 1.6) when 
compared to the control group (baseline 3.8 ± 2.1 g, endpoint 
1.9 ± 1.7 g, effect size -2.1 ± 1.4, p = 0.009). Thirteen (87%) 
VXEMHFWVLQWKHGLVXOÀUDPJURXSZHUHGUXJIUHHDWWKHHQGRI
the study compared to 7 (47%) in the control group (p = 0.020). 
Three (20%) subjects experienced side effects related to di-
VXOÀUDPLQFOXGLQJKHDGDFKHVOXUUHGVSHHFKDQGGURZVLQHVV
One (6.6%, p = 0.282) subject reported headache with pla-
FHER'LVXOÀUDPGLGQRWFDXVHDQHOHYDWLRQRIOLYHUHQ]\PHV
PHDQ$67 XQLWVSHUOLWHULQWKHGLVXOÀUDPJURXS
and AST = 32 ± 3.0 units per liter in the placebo group; mean 
ALT = 46 ± 1.0 units per liter in the disulfiram group 
and ALT = 44 ± 2.2 units per liter in the placebo group).
These data corroborate previous studies that reported 
WKHHIÀFDF\DQGVDIHW\RIGLVXOÀUDPLQVXEMHFWVZLWKDFUDFN
cocaine addiction.1,4 A recent meta-analysis5 evaluated the 
HIÀFDF\DQGDFFHSWDELOLW\RIGLVXOÀUDPDVDQDGGRQWKHUDS\
for cocaine dependence. The authors concluded that there 
LVVFDQWHYLGHQFHVXSSRUWLQJWKHHIÀFDF\RIGLVXOÀUDPLQ 
the treatment of cocaine dependence.5,QDGGLWLRQGLVXOÀUDP
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is inexpensive. However, it has been shown to increase 
the plasma cocaine concentration by three to six fold and 
VLJQLÀFDQWO\ LQFUHDVH FRFDLQHDVVRFLDWHG FDUGLRYDVFXODU 
responses in previous studies of acute and chronic administra-
tion.6,7 Additionally, these studies demonstrated that it did 
QRWVLJQLÀFDQWO\DOWHUWKHEHKDYLRUDOUHVSRQVHVWRFRFDLQH6,7 
However, we did not observe these side effects in our sample.
This study was limited in some respects. The sample size 
ZDV VPDOO EXW WKH UHVXOWVZHUH VLJQLÀFDQW$GGLWLRQDOO\
urine testing was performed only twice in the eight-week 
study period. Therefore, it was necessary to complement 
the evaluation with self-reporting.
:HGHPRQVWUDWHGWKDWGLVXOÀUDPUHGXFHGWKHGUXJXVH
frequency and dose by more than 50% in 60 days and con-
clude that it may be effective and safe as an add-on therapy 
for crack cocaine addiction. However, additional long-term 
VWXGLHVZLWK ODUJHU VDPSOH VL]HVDUHQHFHVVDU\ WR FRQÀUP
WKHVHÀQGLQJV
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7DEOHOutcome measures
%DVHOLQH (QGSRLQW (IIHFWVL]H
3DUDPHWHU 'LVXOÀUDP 3ODFHER 'LVXOÀUDP 3ODFHER 'LVXOÀUDP 3ODFHER SYDOXH
Treatment adherence* - - 14 (93%) 10 (67%) - - .068
Drug frequency use** 4.9 ± 1.5 4.5 ± 1.4 0.6 ± 0.2 1.4 ± 0.9 -4.7 ± 2.6 -2.9 ± 2.0 .015
Drug dosage** 3.9 ± 1.5 3.8 ± 2.1 0.6 ± 0.2 1.9 ± 1.7 -3.7 ± 1.6 -2.1 ± 1.4 .009
Drug free* - - 13 (87%) 7 (47%) 2.5*** - .020
Side-effects* - - 3 (20%) 1 (6.6%) 7.46**** - .283
*n (%); ** mean ± SD; *** number needed to treat (NNT); **** number needed to harm (NNH).
